Rifaximin (L 105)

A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.

Also Known As:

L 105; Xifaxan; 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin; L-105; Redactiv; L105; 2,7-(Epoxy(1,11,13)pentadecatrienoimino)furo(2'',3'':7',8')naphth(1',2':4,5)imidazo(1,2-a)pyridine-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, ( 2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-

Networked: 901 relevant articles (226 outcomes, 226 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	DuPont, Herbert L: 30 articles (01/2020 - 05/2003)
2.	Bajaj, Jasmohan S: 27 articles (10/2022 - 02/2011)
3.	Jiang, Zhi-Dong: 16 articles (06/2013 - 02/2004)
4.	Pimentel, Mark: 15 articles (01/2021 - 10/2006)
5.	Gillevet, Patrick M: 12 articles (01/2022 - 01/2012)
6.	Sikaroodi, Masoumeh: 12 articles (01/2022 - 01/2012)
7.	Fagan, Andrew: 10 articles (10/2022 - 01/2018)
8.	Fuchs, Michael: 10 articles (01/2021 - 02/2011)
9.	Tursi, Antonio: 10 articles (01/2020 - 04/2003)
10.	Dupont, Herbert L: 10 articles (06/2013 - 10/2004)

Related Diseases

1.	Hepatic Encephalopathy 10/06/2016 - "Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). " 04/01/2014 - "Over a 6-month period, treatment with Rifaximin failed to maintain remission from hepatic encephalopathy more effectively than placebo in the studied group." 03/25/2010 - "Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo. " 10/15/2007 - "In contrast, rifaximin is safe and effective in hepatic encephalopathy, but is more expensive. " 12/28/2022 - "Rifaximin is effective in preventing and treating hepatic encephalopathy (HE). "
2.	Diarrhea 05/01/2016 - "The symptoms of all 18 SIBO-positive patients following rifaximin treatment improved notably, particularly diarrhea (P<0.05). " 08/01/2015 - "Clinically, rifaximin 600 mg/d significantly reduced symptoms of travelers' diarrhea (eg, time to last unformed stool vs placebo [32.0 hours vs 65.5 hours, respectively; P=.001]). " 05/01/2016 - "The administration of rifaximin improved the overall gastrointestinal symptoms, particularly diarrhea, in SIBO-positive patients." 10/01/2015 - "Rifaximin can be effective for chronic diarrhea associated with IBS and small intestinal bacterial overgrowth. " 09/01/2011 - "Rifaximin has been shown to be effective in treating and preventing travelers' diarrhea (TD) during the summer season. "
3.	Fibrosis (Cirrhosis) 02/01/2012 - "Rifaximin is effective for the management of HE in patients with cirrhosis, particularly in populations with MELD scores ≤20. " 01/01/2015 - "Adults with cirrhosis and history of overt HE episodes, currently in HE remission, received placebo during the RCT and crossed over to rifaximin 550 mg twice daily during the OLM study. " 03/13/2023 - "Rifaximin improved the liver functional reserve in patients with cirrhosis. " 07/01/2012 - "Intestinal decontamination with rifaximin improved systemic hemodynamics and renal function in patients with advanced cirrhosis." 10/01/2011 - "Patients with cirrhosis in remission from HE (Conn score = 0 or 1) and a documented history of recurrent HE episodes (≥2 within 6 months of screening) were randomised to rifaximin 550 mg twice daily (N = 101) or placebo (N = 118) for 6 months. "
4.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 07/01/2014 - "Clinical studies indicate that rifaximin is beneficial in treating irritable bowel syndrome (IBS). " 05/17/2005 - "Future studies should evaluate whether rifaximin is effective in preventing postinfectious irritable bowel syndrome." 01/01/2021 - "Rifaximin (RFX) is a nonabsorbable BCS class IV drug approved for the treatment of irritable bowel syndrome and effective against Helicobacter pylori. " 06/01/2012 - "Sequential treatment with rifaximin/probiotics seems to be effective for symptom and fermentative profile improvement in irritable bowel syndrome patients." 07/01/2013 - "Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. "
5.	Diverticular Diseases 03/23/2023 - "Rifaximin effectively treats symptomatic uncomplicated diverticular disease (SUDD) and has shown eubiotic potential (i.e., an increase in resident microbial elements with potential beneficial effects) in other diseases. " 02/23/2023 - "Current evidence shows that cyclical rifaximin usage in conjunction with a high-fiber diet is safe and effective for treating symptomatic uncomplicated diverticular disease, while the cost-effectiveness of long-term treatment is unknown. " 06/01/2017 - "The cyclic use of rifaximin, in association with high-fibre intake, is safe and useful for the treatment of symptomatic uncomplicated diverticular disease, even if the cost-efficacy of long-term treatment remains to be determined. " 01/01/2012 - "The evidence from prospective controlled trials suggests that rifaximin is effective for obtaining symptomatic relief in patients with uncomplicated diverticular disease. " 04/01/2011 - "In symptomatic uncomplicated diverticular disease, treatment with rifaximin plus fibre supplementation is effective in obtaining symptom relief and preventing complications at 1 year."

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	Lactulose (Duphalac)
3.	Mesalamine (Mesalazine)
4.	Metronidazole (Metric)
5.	Ciprofloxacin (Cipro)
6.	Rifamycins
7.	Disaccharides
8.	Endotoxins
9.	Norfloxacin
10.	Neomycin

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Aftercare (After-Treatment)
4.	Surgical Portasystemic Shunt (Portosystemic Shunt)
5.	Enema (Enemas)